Comparative Pharmacology
Head-to-head clinical analysis: ACETOHEXAMIDE versus GLUCOTROL XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETOHEXAMIDE versus GLUCOTROL XL.
ACETOHEXAMIDE vs GLUCOTROL XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels (K_ATP), causing membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Also may increase peripheral insulin sensitivity.
Stimulates insulin secretion from pancreatic beta cells by binding to ATP-sensitive potassium channels, causing depolarization and calcium influx, leading to insulin release.
Initial: 250 mg orally once daily; maintenance: 250-1500 mg orally once daily or in divided doses twice daily.
Initial dose: 5 mg orally once daily with breakfast. Titrate by 2.5-5 mg increments at weekly intervals based on glycemic response. Maximum dose: 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (parent drug); ~5-6 hours (active metabolite hydroxyhexamide); clinical context: prolonged in renal impairment due to accumulation of active metabolite
Terminal elimination half-life 2-5 hours; however, due to extended-release formulation, therapeutic effects persist up to 24 hours.
Renal: 85-90% (60-70% as unchanged drug, remainder as hydroxylated metabolite); biliary/fecal: <10%
Renal: ~70% as metabolites (primarily hydroxylated and conjugated metabolites), unchanged drug <10%; Fecal: ~20% via bile.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic